Important note: Information in this article was accurate in 2007. The state of the art may have changed since the publication date.
|
|
Wall Street Journal - April 11, 2007
Avery Johnson, avery.johnson@wsj.com
But as a show of continued resistance in a dispute with the Thai government, Abbott said it wasn't reversing its decision to pull new drug applications in that country.
Abbott has faced public-relations problems over the pricing of its popular AIDS treatment. Health advocates, the AIDS community and more than a dozen faith-based institutional investors voiced criticism when Abbott pulled its drug applications on seven new medicines last month. That move came after Thai authorities decided in January to allow cheaper copycat versions of Kaletra and Plavix, a blood thinner from Bristol-Myers Squibb and Sanofi-Aventis.
Abbott's decision comes ahead of the Abbott Park, Ill., company's annual shareholder meeting on April 27.
The World Health Organization, which approached Abbott about making the pricing move, applauded the decision. And the AIDS Healthcare Foundation, the largest non-governmental AIDS and HIV health-care provider in the U.S., called Abbott's decision "an enormous victory for AIDS activists." But its president, Michael Weinstein, called it "highly vindictive" on Abbott's part not to reinstate the new drug applications, saying, "They're admitting that they're wrong but they still feel the need to punish Thailand." Abbott defends its decision to suspend new medicines because of concerns about patent integrity and the need to fund ongoing drug research.
Abbott will now offer Kaletra for $1,000 per patient per year in Thailand and more than 40 other low- and middle-income countries. That's still more than the $500-a-year price it gives to poorer nations, including Malawi and Kenya, but far less than the U.S. price of roughly $7,000. Abbott says the $1,000 price is 55% lower than the previous price in those nations.
A new formulation of Kaletra that doesn't require refrigeration, called Aluvia in some countries, is one of the drug applications Abbott pulled last month in Thailand, where it says it agrees with a WHO assessment that more work needs to be done to resolve the conflict. That new formulation will be available in the 40 or so countries at a lower price.
Abbott faced a similar standoff with Brazil in 2005 that was resolved when Abbott agreed to lower the price of Kaletra while preserving the company's patent. Brazil had threatened not to honor Abbott's patent on the drug.
070411
WJ070404
Copyright © 2007 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .